RECRUITING

NeoAdjuvant Theranostic Lutetium Study: the Nautilus Trial

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe. Phase 2 will open if the Phase 1 dose is found to be safe. To learn about the safety and effects of 177Lu rhPSMA-10.1 alone and with androgen deprivation therapy (ADT) on patients with high-risk, localized prostate cancer before they have surgery to remove the disease.

Official Title

NeoAdjuvant Theranostic Lutetium Study: the Nautilus Trial

Quick Facts

Study Start:2024-03-29

Study Completion:2026-06-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06066437

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Men ≥18 years of age 2. Histologically documented prostatic adenocarcinoma with an NCCN risk group of high-risk or very high-risk. NCCN High Risk and Very High-Risk criteria shown below. (Network, N.C.C. (2021). * Has no very-high-risk features and has exactly one high-risk feature: * cT3a * Grade Group 4 or Grade Group 5 * PSA \>20 ng/mL * Has at least one of the following: * cT3b-cT4 * Primary Gleason pattern 5 * 2 or 3 high-risk features * \>4 cores with Grade Group 4 or 5 3. Prostate biopsy within 90 days prior to randomization is allowed for entry requirements. Prostate biopsy must be reviewed at MD Anderson Cancer Center. Patients with small cell, neuroendocrine, or transitional cell carcinomas are not eligible 4. ECOG performance status (PS) grade 1 5. No evidence of metastatic disease or clinically positive lymph nodes as documented by technetium99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans. Imaging may be obtained up to 60 days prior to randomization 6. Minimum prostate tumor volume of 1.5 cm3 or greater as measured on prostate MRI within 60 days prior to randomization 7. Distant metastatic disease or clinically positive lymph nodes not identified by conventional imaging including by technetium-99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans but identified PSMA PET is allowed based on provider discretion 8. PSMA expression within the primary tumor with a minimum SUVmax of the primary tumor of at least 8 9. Localized or locally advanced disease deemed by the surgeon to be resectable. Patients must be appropriate candidates for and plan to undergo radical prostatectomy and pelvic lymph node dissection 10. No prior treatment for prostate cancer including prior surgery (excluding transurethral resection of the prostate \[TURP\]), cryoablation, pelvic lymph node dissection, radiation therapy, hormonal therapy or chemotherapy 11. Adequate bone marrow function documented by: * Hemoglobin ≥11 g/dL * Absolute neutrophil count ≥1.5 x 109/L * Platelet count ≥150 x 109/L 12. Adequate renal function defined as creatinine \<1.5 x ULN or estimated glomerular filtration rate \>60 mL/min/1.73 m2 using BSA with CKD-EPI 13. Adequate hepatic function documented by: * Total bilirubin ≤1.5 x ULN * AST ≤2.5 x ULN * ALT ≤2.5 x ULN * Alkaline Phosphatase (ALP) ≤2.5 x ULN 14. Consents to providing whole blood samples for correlative PSMA evaluation of circulating tumor cells and extra cellular vesicles 15. Willing and able to comply with clinic visits and study-related procedures 16. Provide informed consent signed by study patient 17. To avoid risk of drug exposure through the ejaculate (even men with vasectomies), subjects must use a condom during sexual activity while on study drug and for 6 months following the last dose of study drug. If the subject is engaged in sexual activity with a woman of childbearing potential, a condom is required along with another effective contraceptive method consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies and their partners. Donation of sperm is not allowed while on study drug and for 3 months following the last dose of study drug.	1. Prior hormone therapy for prostate cancer including orchiectomy, antiandrogens, ketoconazole, or estrogens (5-α reductase inhibitors allowed), or LHRH agonists/antagonists 2. Currently enrolled in another interventional study 3. Concurrent treatment with systemic corticosteroids (prednisone dose \>10 mg per day or equivalent) or other immunosuppressive drugs \<14 days prior to treatment initiation Steroids that are topical, inhaled, nasal (spray), or ophthalmic solution are permitted. 4. Known evidence of an active infection requiring systemic therapy such as uncontrolled human immunodeficiency virus (HIV), active hepatitis, or fungal infection. Uncomplicated urinary tract infection (UTI) does not qualify as an excluding infection. * Patients with HIV must be on an effective anti-retroviral regimen atleast four weeks prior to enrollment, HIV viral load less than 400 copies/mL and CD4+ T cell counts greater than 350 cell/uL. * Patients with HIV must agree to adhere to anti-retroviral therapy for the entirety of their participation in the protocol unless dictated by treatment toxicities. * Patients on Tenofovir will be excluded as there is a known risk of proximal renal tubule dysfunction leading to renal toxicity. Given that PSMA is expressed on the proximal tubule there is a theoretical risk of overlapping toxicity. 5. History of clinically significant cardiovascular disease including, but not limited to: * Myocardial infarction or unstable angina ≤6 months prior to treatment initiation * Clinically significant cardiac arrhythmia * Deep vein thrombosis, pulmonary embolism, stroke ≤6 months prior to treatment initiation * Congestive heart failure (New York Heart Association class III-IV) * Pericarditis/clinically significant pericardial effusion * Myocarditis * Endocarditis 6. History of major implant(s) or device(s), including but not limited to: * Prosthetic heart valve(s) * Current or prior history of infection or other clinically significant adverse event associated with an exogenous implant or device that cannot be removed 7. Other prior malignancy (exceptions: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) ≤2 years prior to enrollment 8. Has received major surgery within 90 days of first administration of study drug 9. Prior allogeneic stem cell transplantation or recipients of organ transplants or autologous stem cell transplantation at any time MD Anderson Protocol Number: 2022-0500 2022-0500 Version Date 8/29/2023 26 10. Any medical, psychological or social condition that in the opinion of the investigator, would preclude participation in this study 11. Previously received external beam irradiation to the pelvis or to a field that includes more than 30% of the bone marrow or kidneys 12. Previous treatment with any of the following: PSMA-targeted radionuclide therapy, Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation 13. Transfusion of blood products for the sole purpose of meeting the eligibility criteria for this clinical trial 14. Patient has a functionally or anatomically solitary kidney. 15. Patients with Hydronephrosis and a Mag3 Lasix Renogram that demonstrates objective urinary obstruction.

Inclusion Criteria

Exclusion Criteria

1. Men ≥18 years of age
2. Histologically documented prostatic adenocarcinoma with an NCCN risk group of high-risk or very high-risk. NCCN High Risk and Very High-Risk criteria shown below. (Network, N.C.C. (2021).
* Has no very-high-risk features and has exactly one high-risk feature:
* cT3a
* Grade Group 4 or Grade Group 5
* PSA \>20 ng/mL
* Has at least one of the following:
* cT3b-cT4
* Primary Gleason pattern 5
* 2 or 3 high-risk features
* \>4 cores with Grade Group 4 or 5
3. Prostate biopsy within 90 days prior to randomization is allowed for entry requirements. Prostate biopsy must be reviewed at MD Anderson Cancer Center. Patients with small cell, neuroendocrine, or transitional cell carcinomas are not eligible
4. ECOG performance status (PS) grade 1
5. No evidence of metastatic disease or clinically positive lymph nodes as documented by technetium99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans. Imaging may be obtained up to 60 days prior to randomization
6. Minimum prostate tumor volume of 1.5 cm3 or greater as measured on prostate MRI within 60 days prior to randomization
7. Distant metastatic disease or clinically positive lymph nodes not identified by conventional imaging including by technetium-99m (99mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans but identified PSMA PET is allowed based on provider discretion
8. PSMA expression within the primary tumor with a minimum SUVmax of the primary tumor of at least 8
9. Localized or locally advanced disease deemed by the surgeon to be resectable. Patients must be appropriate candidates for and plan to undergo radical prostatectomy and pelvic lymph node dissection
10. No prior treatment for prostate cancer including prior surgery (excluding transurethral resection of the prostate \[TURP\]), cryoablation, pelvic lymph node dissection, radiation therapy, hormonal therapy or chemotherapy
11. Adequate bone marrow function documented by:
* Hemoglobin ≥11 g/dL
* Absolute neutrophil count ≥1.5 x 109/L
* Platelet count ≥150 x 109/L
12. Adequate renal function defined as creatinine \<1.5 x ULN or estimated glomerular filtration rate \>60 mL/min/1.73 m2 using BSA with CKD-EPI
13. Adequate hepatic function documented by:
* Total bilirubin ≤1.5 x ULN
* AST ≤2.5 x ULN
* ALT ≤2.5 x ULN
* Alkaline Phosphatase (ALP) ≤2.5 x ULN
14. Consents to providing whole blood samples for correlative PSMA evaluation of circulating tumor cells and extra cellular vesicles
15. Willing and able to comply with clinic visits and study-related procedures
16. Provide informed consent signed by study patient
17. To avoid risk of drug exposure through the ejaculate (even men with vasectomies), subjects must use a condom during sexual activity while on study drug and for 6 months following the last dose of study drug. If the subject is engaged in sexual activity with a woman of childbearing potential, a condom is required along with another effective contraceptive method consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies and their partners. Donation of sperm is not allowed while on study drug and for 3 months following the last dose of study drug.

1. Prior hormone therapy for prostate cancer including orchiectomy, antiandrogens, ketoconazole, or estrogens (5-α reductase inhibitors allowed), or LHRH agonists/antagonists
2. Currently enrolled in another interventional study
3. Concurrent treatment with systemic corticosteroids (prednisone dose \>10 mg per day or equivalent) or other immunosuppressive drugs \<14 days prior to treatment initiation Steroids that are topical, inhaled, nasal (spray), or ophthalmic solution are permitted.
4. Known evidence of an active infection requiring systemic therapy such as uncontrolled human immunodeficiency virus (HIV), active hepatitis, or fungal infection. Uncomplicated urinary tract infection (UTI) does not qualify as an excluding infection.
* Patients with HIV must be on an effective anti-retroviral regimen atleast four weeks prior to enrollment, HIV viral load less than 400 copies/mL and CD4+ T cell counts greater than 350 cell/uL.
* Patients with HIV must agree to adhere to anti-retroviral therapy for the entirety of their participation in the protocol unless dictated by treatment toxicities.
* Patients on Tenofovir will be excluded as there is a known risk of proximal renal tubule dysfunction leading to renal toxicity. Given that PSMA is expressed on the proximal tubule there is a theoretical risk of overlapping toxicity.
5. History of clinically significant cardiovascular disease including, but not limited to:
* Myocardial infarction or unstable angina ≤6 months prior to treatment initiation
* Clinically significant cardiac arrhythmia
* Deep vein thrombosis, pulmonary embolism, stroke ≤6 months prior to treatment initiation
* Congestive heart failure (New York Heart Association class III-IV)
* Pericarditis/clinically significant pericardial effusion
* Myocarditis
* Endocarditis
6. History of major implant(s) or device(s), including but not limited to:
* Prosthetic heart valve(s)
* Current or prior history of infection or other clinically significant adverse event associated with an exogenous implant or device that cannot be removed
7. Other prior malignancy (exceptions: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) ≤2 years prior to enrollment
8. Has received major surgery within 90 days of first administration of study drug
9. Prior allogeneic stem cell transplantation or recipients of organ transplants or autologous stem cell transplantation at any time MD Anderson Protocol Number: 2022-0500 2022-0500 Version Date 8/29/2023 26
10. Any medical, psychological or social condition that in the opinion of the investigator, would preclude participation in this study
11. Previously received external beam irradiation to the pelvis or to a field that includes more than 30% of the bone marrow or kidneys
12. Previous treatment with any of the following: PSMA-targeted radionuclide therapy, Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation
13. Transfusion of blood products for the sole purpose of meeting the eligibility criteria for this clinical trial
14. Patient has a functionally or anatomically solitary kidney.
15. Patients with Hydronephrosis and a Mag3 Lasix Renogram that demonstrates objective urinary obstruction.

Contacts and Locations

Study Contact

Brian Chapin, MD

CONTACT

(713) 792-3250

bfchapin@mdanderson.org

Marisa Lozano

CONTACT

(713) 792-3250

mllozano@mdanderson.org

Principal Investigator

Brian Chapin, M D

PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

Brian Chapin, M D, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-29

Study Completion Date2026-06-30

Study Record Updates

Study Start Date2024-03-29

Study Completion Date2026-06-30

Terms related to this study

Additional Relevant MeSH Terms

Prostate Cancer